A systematic review of four injection therapies for lateral epicondylosis: prolotherapy, polidocanol, whole blood and platelet-rich plasma

D Rabago, T M Best, A E Zgierska, E Zeisig, M Ryan and D Crane

Br. J. Sports Med. 2009;43;471-481; originally published online 21 Nov 2008; doi:10.1136/bjsm.2008.052761

EDITOR'S CHOICE

A systematic review of four injection therapies for lateral epicondylosis: prolotherapy, polidocanol, whole blood and platelet-rich plasma

D Rabago,[1] T M Best,[2] A E Zgierska,[3] E Zeisig,[4] M Ryan,[5] D Crane[6]

[1] University of Wisconsin School of Medicine and Public Health, Department of Family Medicine, Wisconsin, USA; [2] The Ohio State University, Columbus, Ohio, USA; [3] University of Wisconsin, Madison, Wisconsin, USA; [4] University of Umeå, Umeå, Sweden; [5] University of British Columbia, Vancouver, Canada; [6] Crane Clinic, Chesterfield, Missouri, USA

Correspondence to:
David Rabago, MD, University of Wisconsin School of Medicine and Public Health, Department of Family Medicine, 777 S. Mills St, Madison WI, 53715, USA; david.rabago@fammed.wisc.edu

Accepted 10 November 2008
Published Online First 21 January 2009

ABSTRACT

Objective: To appraise existing evidence for prolotherapy, polidocanol, autologous whole blood and platelet-rich plasma injection therapies for lateral epicondylosis (LE).

Design: Systematic review.

Data sources: Medline, Embase, CINAHL, Cochrane Central Register of Controlled Trials, Allied and Complementary Medicine. Search strategy: names and descriptors of the therapies and LE.

Study Selection: All human studies assessing the four therapies for LE.

Main results: Results of five prospective case series and four controlled trials (three prolotherapy, two polidocanol, three autologous whole blood and one platelet-rich plasma) suggest each of the four therapies is effective for LE. In follow-up periods ranging from 9 to 108 weeks, studies reported sustained, statistically significant ($p<0.05$) improvement in visual analogue scale primary outcome pain score measures and disease-specific questionnaires; relative effect sizes ranged from 51% to 94%; Cohen's d ranged from 0.68 to 6.68. Secondary outcomes also improved, including biomechanical elbow function assessment (polidocanol and prolotherapy), presence of abnormalities and increased vascularity on ultrasound (autologous whole blood and polidocanol). Subjects reported satisfaction with therapies on single-item assessments. All studies were limited by small sample size.

Conclusions: There is strong pilot-level evidence supporting the use of prolotherapy, polidocanol, autologous whole blood and platelet-rich plasma injections in the treatment of LE. Rigorous studies of sufficient sample size, assessing these injection therapies using validated clinical, radiological and biomechanical measures, and tissue injury/healing-responsive biomarkers, are needed to determine long-term effectiveness and safety, and whether these techniques can play a definitive role in the management of LE and other tendinopathies.

Lateral epicondylosis (LE) (''tennis elbow'') is an important condition of the upper extremity with an incidence of up to 4–7/1000 patients per year,[1–3] having a substantial impact on athletes and workers.[4 5] A subset of patients are refractory to non-surgical therapy including relative rest, eccentric exercise and corticosteroid injections and suffer long-term pain and disability on average lasting for 6 months to 2 years, regardless of therapy.[6 7] Our understanding of the pathophysiology of lateral elbow overuse injury has changed in recent years.[8–11] The pathophysiological hallmark of tendinopathy is the presence of degenerative changes, including neovascularity and disorganised collagen fibres.[9 12] The precise cause of degeneration and pain in patients with a tendinopathy is not clear; mechanical, vascular, neural and ''failure of healing'' aetiological models have all been proposed.[13]

Treatment approaches for LE vary widely and lack definitive evidence. Non-steroidal anti-inflammatory drugs and corticosteroid injections have traditionally been used but have not been shown to be more effective than watchful waiting in the long term.[14 15] Eccentric exercise regimens have shown some efficacy compared with age–gender–activity-matched controls, though a subcohort of patients remain refractory.[16] Other non-surgical therapies have been evaluated for LE refractory to such conservative measures; none have been shown to be consistently effective.[17–19] Polidocanol, prolotherapy, autologous whole blood and platelet-rich plasma (PRP) injection therapies have reported promising outcomes for LE and other sport-related tendinopathies.

Polidocanol is a vascular sclerosant. In treating tendinopathy, it is used to sclerose areas of high intratendinous blood flow, sometimes termed ''neovessels'', which are seen histopathologically[12] and in vivo under high resolution ultrasound with colour Doppler. Neovascularity is thought to be associated with the underlying mechanism of LE and other overuse tendinopathies,[20 21] though whether it is a causal agent in the pathophysiology of tendinopathy is not clear.[22] A recent study reported that sustained sclerosis of neovascularity in LE was a good predictor of positive clinical effect at 2 years.[23] Several randomised controlled trials (RCTs) and prospective case series have reported positive effects of polidocanol therapy for patellar, epicondylar and Achilles tendinopathies.[24–26]

The use of prolotherapy dates to the 1930s,[27] when it was developed for pain associated with presumed ligament laxity. Although several injection agents have been used, hyperosmolar dextrose and morrhuate sodium (also a vascular sclerosant) are the most popular[28] and best studied agents. A recent systematic review identified 42 studies, over 50% of which evaluated prolotherapy for back pain, the remainder largely for painful conditions such as osteoarthritis and injuries associated with ligament laxity.[29] Prolotherapy has also been used to treat tendinopathy of elite athletes[30] and LE.[31]

Autologous whole blood and the blood product PRP have been used as injectants for tendinopathy with the aim of providing cellular and humoral mediators to induce healing in areas of degeneration. Autologous whole blood injections have been used for medial[32] and lateral epicondylosis[33] and plantar fasciitis.[34]

Platelet-rich plasma is prepared from autologous whole blood, which is centrifuged to concentrate platelets in plasma. The intention is to augment the native healing process at the site of pain through the action of platelet-derived growth factors (PDGFs). Platelets contain at least six PDGFs vital to bone and soft tissue healing (table 1). The basic and clinical science of PRP has been reviewed.[35] Since the early 1990s PRP has been used for its purported ability to improve soft tissue healing and bone regeneration. The use of PRP is being intensely studied and reports suggest that clinical use is increasing rapidly for LE,[36] rotator cuff repair,[37 38] acute and chronic muscle strain, muscle fibrosis, ligamentous sprains, and joint capsular laxity (David Crane, MD, personal communication).

These therapies, which target the diseased tendon tissue directly, may interrupt the degenerative cycle associated with tendinopathy and allow the return of the native healing process, ultimately leading to improvement in clinical outcomes. None have been directly compared in any trial setting, but each has been assessed for LE. Because of the potential for prolotherapy, polidocanol, whole blood and PRP injection therapies to be effective for tendinopathies, we undertook a systematic review of the literature for each technique for the treatment of refractory LE.

METHODS

Inclusion criteria included human clinical trials of any design involving pre- and post-treatment assessment evaluating any of the four injection therapies for LE. A literature search was performed by the lead author (DR) and library staff of the following electronic databases: Medline (Ovid Web, 1950–2008 and Medline In-process & Other Non-Indexed Citations), Embase (1974–2008), CINAHL (1982–2008), the Cochrane Central Register of Controlled Trials (through third quarter 2008) and Allied and Complementary Medicine (1985–2008). Search strategies utilised the name of each intervention and the names of the injectants (table 2). Reports not cited in the databases above were searched using the Google search engine and the National Institutes of Health (NIH) CRISP electronic database using relevant anatomical descriptors and therapy names. The reference lists of identified studies were reviewed to identify potentially eligible studies. E-mail or phone contact was attempted with relevant author(s) or principal investigator(s) of included articles or abstracts when additional information was needed.

Table 1 Synopsis of growth factors contained in platelet-rich plasma[35]

Growth factor	Source	Function
Transforming growth factor-beta, TGF-β	Platelets, extracellular matrix of bone, cartilage matrix, activated TH_1 cells and natural killer cells, macrophages/monocytes and neutrophils	Stimulates undifferentiated mesenchymal cell proliferation; regulates endothelial, fibroblastic and osteoblastic mitogenesis; regulates collagen synthesis and collagenase secretion; regulates mitogenic effects of other growth factors; stimulates endothelial chemotaxis and angiogenesis; inhibits macrophage and lymphocyte proliferation
Basic fibroblast growth factor, bFGF	Platelets, macrophages, mesenchymal cells, chondrocytes, osteoblasts	Promotes growth and differentiation of chondrocytes and osteoblasts; mitogenetic for mesenchymal cells, chondrocytes and osteoblasts
Platelet-derived growth factor, PDGFa-b	Platelets, osteoblasts, endothelial cells, macrophages, monocytes, smooth muscle cells	Mitogenetic for mesenchymal cells and osteoblasts; stimulates chemotaxis and mitogenesis in fibroblast/glial/ smooth muscle cells; regulates collagenase secretion and collagen synthesis; stimulates macrophage and neutrophil chemotaxis
Epidermal growth factor, EGF	Platelets, macrophages, monocytes	Stimulates endothelial chemotaxis/ angiogenesis; regulates collagenase secretion; stimulates epithelial/ mesenchymal mitogenesis
Vascular endothelial growth factor, VEGF	Platelets, endothelial cells	Increases angiogenesis and vessel permeability; stimulates mitogenesis for endothelial cells
Connective tissue growth factor, CTGF	Platelets through endocytosis from extracellular environment in bone marrow	Promotes angiogenesis, cartilage regeneration, fibrosis and platelet adhesion

Identification of eligible studies

The titles and abstracts of all identified studies were screened by the study librarian and the lead author (DR). Studies whose title and abstract clearly indicated that the paper met criteria were reviewed. A description of excluded studies follows.

Data extraction

The data collection strategy for the methods and results sections of identified papers was determined a priori. Data from prospective case series was extracted by the lead author (DR). Two unblinded authors (DR, TB) assessed each controlled study. Data were extracted using a pre-existing technique.[39] The RCT strength was assessed using the Delphi[40] controlled trial internal validity assessment. Disagreements were resolved by consensus. Using these instruments, the methods and results of each study were described and an overall quality score assigned. Where possible, several measures of ''effect size'' at various follow-up time points were calculated by the authors. (1) ''Per cent improvement'' was calculated for all intervention arms as the change in pain score divided by the baseline score multiplied by 100%. (2) Cohen's d was used as published or, if not provided, was calculated according to one of two formulas: (a) for controlled trials, $d = [M_1 - M_2]/SD_{pooled}$, where M_1, M_2 were the means in the two groups, and $SD_{pooled} = \sqrt{[(SD_1^2 + SD_2^2)/2]}$; (b) for pre–post assessments, d = [mean of the pre–post difference]/[SD of the mean]; if data for formula ''b'' was not available, then formula ''a'' was applied, when possible. 3) In one study,[33] effect size was estimated based on the Z value of the Wilcoxon Signed Rank Test according to the formula: $Z/\sqrt{N}$, where N equals the number of observations over the two time points.[41] An overall evidence grade for each technique was assigned by the lead author (DR) based on the Strength of Recommendation Taxonomy criteria.[42]

RESULTS

The search identified 21 reports as possibly relevant; the abstract of each was reviewed. Nine studies met the eligibility criteria. Excluded studies were: general reviews (three), surgical (one), basic science (one), for different indications (three) or editorials (two), or assessed a non-reviewed therapy (one).

Table 2 Search strategy

Step	Search Strategy
1	Tennis Elbow.mp. or ((Tend?nopath*.mp. or tend?nitis or tend?nosis) and Elbow*).mp. or Lateral adj3 Epicondyl*.mp. or Chronic adj3 Elbow adj3 Pain.mp.
2	Sodium adj2 Morrhuate.mp. or Dextrose.mp. or Prolotherap*.mp. or Polidocanol*.mp. or ((Platelet adj1 Rich) adj3 Plasma).mp. or Autologous adj3 Injection*.mp. or ((Whole adj1 Blood) adj2 Injection)*.mp. or Sclerotherap*.mp.
3	1 and 2

Differences in the methods of the four therapies and in outcome measures used prevented pooling of data. Heterogeneity and inter-rater agreement of controlled study quality scoring were not formally assessed. First authors were queried about ambiguous elements of their studies. There was no significant disagreement between the raters.

Study outcomes

We identified nine eligible reports, four controlled studies and five prospective case series evaluating effects of prolotherapy (three), polidocanol (two), autologous whole blood (three) and PRP (one) therapies for LE assessing 208 adult subjects (tables 3,4). The common primary inclusion criteria were elbow pain for a minimum of 2 months and being refractory to one or more conservative therapies. The subjects were 19–66 years old, diagnosed with LE due to a variety of work and recreational activities. No study reported the inclusion of elite athletes. Subjects had an average pain duration ranging from 2 to 102 months. Subjects in three studies[25 33 43] underwent ultrasound evaluation as part of the diagnosis and injection protocol and had areas of structural change and neovascularisation within the common extensor tendon. The controlled studies[25 31 36 44] were of moderate to high quality, scoring 5–9/9 on the Delphi assessment. All controlled studies compared active solution with a comparison solution with either vasoactive control agents (lidocaine/adrenaline or bupivacaine/adrenaline)[25 36] or saline.[31] The primary outcome of each study was pain on a visual analogue scale (VAS) or pain questionnaire,[44] though the denominator and specific issue addressed varied slightly. Improvement ranged from 51%[25] to 94%[45] for the active groups compared with baseline status; Cohen's d effect size ranged from 0.68[33] to 6.68,[31] indicating a strong effect. Cohen's d was not calculated for some studies due to insufficient data.[25 36 45 46]

In a prospective case series[43] of subjects receiving ultrasound-guided polidocanol treatment, VAS scores improved by 37% at 3 months ($p<0.05$) and by 55% at 8 months ($p<0.01$). Grip strength significantly improved at 3 and 8 months. Structural defects and vascularity on ultrasound were improved at 8 months. In a subsequent double-blind RCT, Zeisig *et al*[25] compared polidocanol with vasoconstrictive lidocaine/adrenaline injections. Both groups improved their VAS pain scores at 3 months, without significant differences between the groups. Three months following the first treatment session, subjects in both study groups who were unsatisfied with clinical results were offered an additional injection session with polidocanol. Follow-up at 12 months after enrolment showed that additional polidocanol injections improved VAS scores by 51% and 47% compared with baseline in subjects receiving initial polidocanol and adrenaline injection respectively.

In two RCTs,[31 44] and one prospective case series,[45] subjects received either prolotherapy or normal saline. Active subjects in Scarpone *et al* reported improvement of 90% at 16 weeks compared with 22% for controls ($p<0.001$), with four prolotherapy subjects reporting complete pain resolution. In a small RCT, Glick *et al*, subjects reported 66% improvement on a disease-specific questionnaire compared with 11.5% for controls ($p = 0.09$). In a prospective case series, Lyftogt[45] reported 94% improvement compared with baseline scores using a novel subcutaneous injection technique ($p<0.05$).

Three prospective case series assessing autologous whole blood were identified.[33 46 47] Each study reported significant ($p<0.05$) improvement compared with baseline: Edwards *et al* reported 88%,[47] Gani *et al* reported 64%[46] and Connell *et al*[33] reported a median score of 0.

In a non-randomised controlled trial[36] comparing a single treatment session of PRP with control injections, PRP subjects improved by a mean of 81% by 27 weeks. PRP subjects were further followed to a mean of 25.6 months, at which point the authors reported 93% pain reduction compared with baseline. Controls reported 17% improvement at 4 weeks; three of five control subjects dropped out before the 8 week follow-up and the remaining two control subjects were not followed further.

Secondary outcome measures also improved in all eight studies. Mishra *et al*[36] reported significant improvement on the Mayo Elbow-Performance Index. Each study assessing whole blood injections reported significant improvement in Nirschl scores.[33 46 47] Zeisig *et al*[25] and Scarpone *et al*[31] reported significant improvement in maximal grip strength compared with baseline in the intervention groups. Scarpone *et al* also reported improved isometric strength in the prolotherapy group compared with controls. Zeisig *et al*[43] and Connell *et al*[33] reported decreased structural defects and neovascularity on ultrasound, though these were not reliably correlated with clinical gains. Treatment satisfaction on single-item assessments was reported by 78% of the "polidocanol only" subjects at 12 months,[25] by 93% of the PRP subjects at 25.6 months,[36] and by 100% of subjects in Lyftogt *et al*.[45] Scarpone *et al*[31] reported that prolotherapy subjects qualitatively reported maintenance of treatment effects at 12 months.

DISCUSSION

Prolotherapy, polidocanol, autologous whole blood and PRP injection therapies have received attention in the treatment of tendinopathies among elite athletes and primary care patients. This is the first systematic review to compare these techniques for a single condition, LE. Each of the studies reviewed is small, and their methodological limitations prevent a consensus recommendation on the use of any of the three therapies compared with another at this time. However, the large effect sizes reported by all studies are compelling and suggest several areas of clinical, theoretical and research interest.

Clinical implications

In a technique that places injectant on or near a degenerative area of the tendon–bone insertion, each injectant appears safe. Though not powered to detect rare local or systemic negative effects, no study evaluating any of these therapies for musculoskeletal conditions has reported serious adverse events. Two systematic reviews of prolotherapy[29 48] and a study of negative consequences of prolotherapy[28] reported only minor side effects consistent with injection trauma, suggesting that the prolotherapy injectants themselves are safe. Though vascular sclerosants can theoretically cause tissue necrosis, this was not reported in these studies. The transmission of blood-borne disease is a possibility in each therapy, and underscores the need for universal precautions, including the use of gloves and appropriate handling and disposal of medical waste.

With moderate-to-large effect sizes that far exceed minimal clinically relevant effect sizes for chronic pain,[49] and which are sustained over 12[25 31] to 25 months[36] compared with baseline or comparison groups, each technique appears potentially effective for refractory LE, thus expanding treatment options for patients who have failed conservative care. In one author's clinic (EZ) the stepwise treatment algorithm for LE is: (1) conservative measures including eccentric exercise, (2) polidocanol injections,

Table 3 Clinical trials of prolotherapy (PrT), polidocanol (Pdl), autologous whole blood (AWB) and platelet-rich plasma (PRP) injection therapies for LE

Study/Type	Subjects	Intervention	Injectant/control	Ancillary treatment	Follow-up/outcome measures	Results	Effect size of pain score (Cohen's d and % improvement)	Comments	Delphi score, x/9
Zeisig *et al* 2008[25] Polidocanol RCT	36 (16 female); mean age 46 (27–66) years; LE pain for mean 21 months; failed ⩾1 of: PT, eccentric PT, NSAIDs, steroid injections, orthotics, acupuncture, ultrasound, botox injections	Pdl: at 0 weeks, and optional at 12 weeks; U/S-guided, to "neovessels"; after their 1st injection session (in Pdl or comparison group), all subjects were offered Pdl injections at 12 weeks if unsatisfied with effects of first injection; 0.5–1 ml total	► Pdl: 10 mg/ml;	None	► 12, 52 weeks;	► no between-group differences in pain score, grip strength or satisfaction;	Compared with baseline:	At 12 weeks, unsatisfied control subjects were crossed-over to Pdl injections, if desired	9
			► active comparison group: lidocaine + adrenaline; optional Pdl injections at 12 weeks (cross-over)		► exertional pain (0–100 VAS); maximum grip strength; subject satisfaction (0–100% scale)		Cohen's d: N/A Pdl improved: 23%, adrenaline improved: 13% ► 52 weeks: Cohen's d: N/A; Pdl improved: 51% ($p<0.05$), adrenaline/Pdl improved: 47%		
Zeisig *et al* 2006[43] Polidocanol prospective case series	11 (7 female); mean age 46 (33–63) years; LE pain for mean 23 months; failed ⩾1 of: PT (7), NSAIDs (11), steroid injection (7), orthotics (5), acupuncture (2), ultrasound (2)	Pdl: at 0 weeks;		None	► 12, 35 weeks;	► Pain improved by 28 points at 12 weeks and 41 points at 35 weeks ($p<0.05$);	Compared with baseline:	Prospective case series	N/A
		0.4–1.1 ml total			► exertional pain (0–100 VAS); maximum grip strength; structural defect (yes/no) and degree of vascularity (0–2 scale) on U/S; subject satisfaction (0–100% scale)	► grip strength, presence of structural defect and degree of vascularity improved at 12 and 35 weeks ($p<0.05$);	► 35 weeks:		

Continued

Table 3 Continued

Study/Type	Subjects	Intervention	Injectant/control	Ancillary treatment	Follow-up/outcome measures	Results	Effect size of pain score (Cohen's d and % improvement)	Comments	Delphi score, x/9
						► Mean subject satisfaction 83%	Cohen's d: 1.4 Improved: 55% ($p<0.05$)		
Scarpone *et al* 2008[31] Prolotherapy RCT	24 (13 female); mean age 45.7 (19–62) years; LE pain for mean 1.9 years; failed NSAIDs, relative rest, PT, two steroid injections	PrT: at 0, 4, 8 weeks, to tender points at supracondylar ridge, lateral epicondyle and annular ligament;	► PrT: 10.7% dextrose + 14.7% sodium morrhuate	None	► 8, 16, 52 weeks	► At 16 weeks, pain improved ($p<0.05$) by 4.6 points compared with baseline, and 3.6 points compared with control;	Compared with baseline:	Lack of consistent, long-term follow-up; unconventional assessment of grip strength	8
		1.5 ml total	► Control: 0.9% saline		► Resting elbow pain (0–10 VAS); isometric strength; grip strength; continuity of improvement at 52 weeks	► at 16 weeks, isometric strength improved ($p<0.05$) compared with baseline and control; grip strength improved ($p<0.05$) compared with baseline;	► 8 weeks:		
						► at 52 weeks, qualitative improvement compared with control	PrT improved: 35% ($p<0.05$); control improved 20% ► 16 weeks: PrT improved 90% ($p<0.05$), control improved 22% Compared with controls: PrT improved 68%; Cohen's d: 6.68:		
Glick *et al* 2008 Prolotherapy RCT	8 (2 female), mean age 50 years; LE pain for longer than 3 months	PrT: at 0, 3 and 6 weeks to the lateral epicondyle and tender extensor tendon origin; 5 ml total	► PrT: 15% dextrose and 1% lidocaine	All subjects used at-home stretching	► 9 weeks; McGill Pain Questionnaire (0–45), Physical Composite score of MOS SF-36	► McGill score improved ($p = 0.086$) by 7.75 points compared with baseline and 7 points compared with control	Compared with baseline:	Lack of disease-specific outcome measure, short follow-up period	7
			► Control: 0.9% saline and 1% dextrose			► Physical Composite score improved ($p = 0.05$) by 8.4 points compared with baseline and control. Cohen's d statistic calculated to be 1.57 and 1.78 for the McGill and MOS measures respectively	► 9 weeks: PrT improved: 66% ($p<0.05$); control improved 11.5% Compared with controls: ► 9 weeks: Cohen's d = 1.6 Improved: 54.5% ($p<0.09$)		
Lyftogt 2007[45] Prolotherapy Prospective case series	20 (9 female), mean age 39 (24–64) years; LE pain for mean 6 months	PrT: weekly sessions for mean 8 weeks; to tender points at common extensor tendon; 0.5–1.0 ml total	► PrT: 20% glucose + 0.1% lidocaine	Modified daily activity	► Weekly during intervention (mean duration of 7.2 weeks); final follow-up at mean 19 months;	► pain improved by 6.8 points compared with baseline ($p<0.05$);	Compared with baseline:	Unconventional subcutaneous prolotherapy technique with 10–15 injections per session	N/A

Continued

Table 3 Continued

Study/Type	Subjects	Intervention	Injectant/control	Ancillary treatment	Follow-up/outcome measures	Results	Effect size of pain score (Cohen's d and % improvement)	Comments	Delphi score, x/9
			► Placebo: N/A		► elbow pain (0–10 VAS); subject satisfaction (yes/no)	► 100% of subjects satisfied	► mean 19 months: Cohen's d: N/A Improved: 94% ($p<0.05$)		
Edwards *et al* 2003[47] Autologous Whole Blood Prospective case series	28 (14 female); LE pain for at least 3 months; failed two or more conservative therapies	AWB: at 0, 6 weeks, and optional at 12 weeks; to extensor carpi radialis brevis; 2 ml total	► AWB: whole autologous blood + 2% lidocaine or 0.5% bupivacaine;	400 splint; 3 weeks of motion restriction, then 3 weeks of stretching exercises	► Every 6 weeks for at least 26 weeks (mean 9.5 months);	► pain improved by 5.5 points by a mean of 3 weeks after last injection.	Compared with baseline:	Prospective case series; no statistical comparisons reported	N/A
			► control: N/A		► pain at rest (0–10 VAS); Nirschl scale (1–7)	► Nirschl scale improved by 4.5 points by a mean of 3 weeks after last injection	► after first injection: Cohen's d: 1.7 Improved: 40% ($p<0.05$); ► after second injection: Cohen's d: 3.0 Improved: 88% ($p<0.05$)		
Connell *et al* 2006[33] Autologous Whole Blood Prospective case series	35 (12 female); mean age 40.9 (26–62) years; LE pain for mean 13.8 months; failed each of: rest, PT, steroid injection	AWB: 0, 4 weeks, and optional at 8 weeks; U/S-guided, to area of maximal structural discontinuity; 2 ml total	► AWB: autologous whole blood;		► 4, 26 weeks	► Pain: median score 9, 6 and 0 at baseline, 4 and 26 weeks, respectively;	*Compared with baseline:	Prospective case series; raw data, mean scores and statistical comparisons for some of the outcomes not provided	N/A
			► Control: N/A		► pain (0–10 VAS); Nirschl scale (1–7); U/S-assessed tendon thickness, hypoechogenicity, neovascularity; treatment satisfaction (yes/no)	► Nirschl scale: median score 6, 4 and 0 at baseline, 4 and 26 weeks, respectively;	► 4 weeks:		
						► U/S: mean tendon thickness, hypoechogenicity and neovascularity improved ($p<0.001$)	Cohen's d: 0.68;		
						► 91% of subjects satisfied	► 26 weeks: Cohen's d: 0.72		

Continued

Table 3 Continued

Study/Type	Subjects	Intervention	Injectant/control	Ancillary treatment	Follow-up/outcome measures	Results	Effect size of pain score (Cohen's d and % improvement)	Comments	Delphi score, x/9
Gani *et al* 2007[46] Autologous Whole Blood Prospective case series	26 (16 female); mean age 34 (21–54) years; LE pain for mean 2.1 years; failed rest, NSAIDs, activity modification, steroid injection	AWB: at 0 weeks, and optional at 6 weeks	► AWB: whole autologous blood;	Sling for 1 week, then rest and stretching exercises; no heavy lifting for 3 weeks	► Weekly, up until 35 weeks on average;	► Pain improved ($p<0.05$) by 2.1 points at 35 weeks;	Compared with baseline:	Prospective case series;	N/A
			► control: N/A			► Nirschl scale improved ($p<0.05$) from mean score 5.5 to 2.1 at 35 weeks	► after up to two injections: Cohen's d: N/A Improved: 64% ($p<0.05$)	unconventional Likert scale as primary outcome	
Mishra *et al* 2006[36] Platelet-Rich Plasma non-randomised controlled trial	20 adults; 15 PRP subjects: mean age 48.1 years, LE pain for mean 15.3 months; five control subjects: mean age 42 years, LE pain for mean 11.8 months; failed one or more of: NSAIDs, PT, bracing, steroid injection	PRP: single injection at 0 weeks	► PRP: pH 8.4, approximately 3.3 million platelets per treatment session	► Stretching exercises for 2 weeks, then formal strengthening exercise programme for 2 weeks	► 8, 26, 108 weeks;	► At 8 weeks, pain improved ($p<0.05$) by 33 points compared with control; compared with baseline, pain improved ($p<0.05$) by 47, 71 and 80 points at 8, 26 and 108 weeks, respectively;	Compared with baseline:	Non-randomised design; three of five control subjects left study at 8 weeks; injected local anaesthesia used in both groups; 108 - week Mayo score not reported	5
			► Control: bupivacaine + adrenaline		► exertional pain (0–100 VAS); Mayo Elbow Performance Index; % subjects satisfied with therapy	► 93% of subjects satisfied	► 8 weeks: Cohen's d: N/A Improved: 60% ($p<0.05$); ► 27 weeks: Cohen's d: ; N/A Improved: 81% ($p<0.05$) Compared with controls: ► 8 weeks: N/A		

AWB, autologous whole blood; LE, lateral epicondylosis; N/A, not applicable; NSAIDs, non-steroidal anti-inflammatory drugs; PdI, polidocanol; PRP, platelet-rich plasma; PrT, prolotherapy; PT, physical therapy; U/S, ultrasound; VAS, visual analogue scale

*Median scores reported, per cent change therefore not calculated; Cohen's d calculated using reported Z statistic.

Results reported for a final follow-up unless stated otherwise.

Table 4 Comparison of the Strength of Evidence Taxonomy (SORT) recommendation[42] and methodological considerations for each injection therapy when used to treat lateral epicondylosis, as practised in assessed papers

Injectant	SORT recommendation	Anatomical evaluation	Injectant preparation	Added injectants	Injection technique	Volume injected	Injection schedule
Polidocanol	2B	Palpatory exam, U/S and Colour Doppler exam; elbow structures are examined while seated, with arm resting on a table in 70–80 degrees of elbow flexion and wrist pronation	None; stock polidocanol 10 mg/ml solution used	None	U/S and Colour Doppler-guided injections at the common extensor origin at the lateral epicondyle. The aim is to inject polidocanol intravascularly; however, due to the small size of neovessels, the solution may be delivered perivascularly.	0.4–1.1 ml; one injection, using three to five needle sticks to ensure coverage of neovessels	One to two injection sessions, approximately 3 months apart
Autologous Whole Blood	3C	Palpatory exam ± U/S exam	2 ml autologous whole blood collected at the time of injection	Topical anaesthetic	Injection to undersurface of extensor carpi radialis brevis[46 47] or area of maximal tendon disruption on U/S exam[33]	2 ml	Study-dependent; one to three injection sessions, approximately 1 month apart
Platelet-Rich Plasma	2B	Palpatory exam	Preparation of syringes with anticoagulant, then 20–60 ml of whole blood is drawn from peripheral vein Blood is centrifuged Preparation of the injection site with local anaesthetic	Proprietary, kit-dependent; anticoagulant	U/S-guided single injection, using five to seven needle sticks, 1 cm distal to the origin of the common extensor tendon	1 ml per cm^2 of involved tissue, up to total of 2–3 ml	Single injection session
Prolotherapy	1B	Palpatory exam	None; injectant prepared from stock solution of 50% dextrose and 5% morrhuate sodium	Saline and topical anaesthetics: lidocaine and sensorcaine	Injection at tender entheses of ligament and tendon structures at the lateral epicondyle and supracondylar ridge; precise location and number of injections per session as well as the number of sessions per treatment course are patient-specific, determined by exam	0.5 ml per injection, three to five injections per session	3 monthly sessions

U/S, ultrasound

and (3) surgery, which, in the author's experience, is rarely required. A similar algorithm has been reported for Achilles tendinopathy.[50]

The ease of clinical application of these techniques varies. Each requires routine medical knowledge of diagnostic, anatomical and joint injection skills. However, the procurement and processing of the injectants, and the required assessment associated with each therapy, vary. For example, polidocanol therapy calls for ultrasound and colour Doppler exam and specialised skills to visualise increased vascularity. PRP therapy requires investment in a centrifuge and blood processing equipment, and corresponding skills. Individual characteristics of the platelet preparation differ slightly between companies based on a number of factors; several reviews are available.[35 37] Prolotherapy has limited start-up costs and is the easiest to implement. However, it may be more labour-intensive; in the reviewed studies, it required three treatment sessions, whereas the other three therapies typically used one or two treatment sessions.

Theoretical implications

The cause of pain in LE and the precise mechanism of action of the four injectants are unclear. The reviewed studies offer an opportunity to address aspects of both issues. Researchers have suggested that clinical effects of these therapies may in part result from the compressive effects of injected solutions, needle trauma, and irritant effects of blood.[25 29] The studies, however, suggest that the "active" group injectants themselves provide the majority of therapeutic effects. No significant volume-related effect of comparison saline or dilute adrenaline injection was found in three RCTs.[31 36 44] Similarity in outcomes in Zeisig *et al*[25] may be explained by the actions of the two solutions: vasosclerosis may have a slightly greater effect on the neurovascular milieu than does temporary vasoconstriction. However, the study design did not allow additional adrenaline injections, so whether polidocanol is more effective than adrenaline for LE remains unclear. Mishra *et al* found no significant effect from mild preinjection fenestration. It is unclear whether the more active fenestration performed by Connell *et al* influenced outcomes, as no other study reported such a preinjection procedure.

The notion that these injectants exert a biological effect independent of needle trauma or volume-related effects is consistent with clinical, animal model and in vitro evidence. Recent clinical studies documented that areas of increased vascularity are associated with painful LE,[51] have significant sensory innervation, and are linked with higher concentrations of the pain modulators glutamate and calcitonin gene-related peptide.[52] Sclerosing of such structures in Achilles and patellar tendinopathy has also led to reduction in pain.[24 26]

Prolotherapy with dextrose with or without morrhuate sodium has been reported to decrease pain and improve function in a variety of tendinopathies.[30 53 54] The historical hypothesis that prolotherapy causes an inflammatory response leading to reduced tendon and ligament laxity[55] has not been confirmed. Two recent studies did not detect increased inflammation or decreased laxity following prolotherapy in a rat model.[56 57] Morrhuate sodium is in the same chemical class as polidocanol and likely acts as a vascular sclerosant. Animal model data support a biological effect. Rabbit medial collateral ligaments injected with morrhuate sodium were significantly stronger (31%), larger (47%), thicker (28%) and had larger collagen fibre diameter (56%) than saline-injected controls.[58] Rat patellar tendons injected with morrhuate sodium were able to withstand a mean maximal load of 136% of the uninjected control tendons.[59] Hyperosmolar dextrose is also a mild vascular sclerosant, though its potential effect in tendinopathy is not well understood. A hyperosmolar glucose environment has been shown to increase platelet-derived growth factor expression and upregulate multiple mitogenic factors[60–62] that may act as signalling mechanisms in tendon repair. Lyftogt has suggested that neurogenic inflammation[63] may contribute to pain in LE, and that subcutaneous injections of hyperosmolar dextrose target inflamed branches of the posterior antebrachial and medial antebrachial cutaneous nerves (Lyftogt personal communication, 2008). However, neither growth factor nor "neurosclerotic" effects have been confirmed in a tendinopathy model.

PRP injections make use of activated platelets which discharge bioactive signalling molecules including three adhesion molecules and seven growth factors. A total of 21 of 28 clinical reports, largely from the maxillo-facial and wound care fields, have reported positive PRP effects on bone and wound healing. However, many studies had a small sample size and used different methods for platelet processing, thereby preventing definitive conclusions.[35] Most PRP-related in vitro and animal model science reports come from the orthopaedic literature on bone healing and report a variety of cellular and growth factor effects of potential importance to tendon healing.[35] Studies assessing PRP effects for soft tissue healing showed increased anabolic gene expression in horse flexor tendons[64] and proliferation of tendon cells and production of VEGF.[65 66] Two large animal studies have recently reported improved healing of repaired dog and porcine cruciate ligaments following PRP therapy.[67 68]

Research implications

Basic science research is needed to elucidate the mechanism of action for each injection therapy. Sufficiently powered clinical trials should evaluate efficacy and effectiveness of each of the therapies compared with eccentric exercise and with each other. Research would benefit from the unification of outcome measures across these studies, which should include clinically relevant, patient-reported and objectively assessed outcomes such as pain, function and disability. Assessment of tissue injury/healing-sensitive biomarkers may enhance our understanding of the processes underlying treatment efficacy.

What is already known on this topic

Therapies for lateral epicondylosis and other overuse tendinopathies are varied; none have been found to definitively reduce pain and improve function. Data suggestive of efficacy for prolotherapy, polidocanol, autologous whole blood and platelet-rich plasma injections have been reported in limited, pilot-level studies but have not been directly compared.

What this study adds

This systematic review compares studies assessing prolotherapy, polidocanol, autologous whole blood and platelet-rich plasma injections for a single tendinopathy, lateral epicondylosis. Nine studies document a large effect size for each technique; "per cent change compared with baseline" and "Cohen's d" ranged from 51% to 94%, and 0.68 to 6.68, respectively.

Existing preliminary data suggest that these injection therapies have a disease-modifying potential; therefore, imaging studies, such as MRI and/or ultrasound with colour Doppler, may also be useful in addressing the mechanisms by which these agents promote healing. Whether results can be generalised across different patient populations (e.g. athletes and occupational workers) remains an important question to be answered. Larger studies assessing PRP, prolotherapy and autologous stem cell injection for LE are currently in progress (personal communication: Allan Mishra, Ron Glick and David Connell).

CONCLUSIONS

Existing data for prolotherapy, polidocanol, autologous whole blood and PRP injection therapies for refractory LE suggest effectiveness, but are limited by lack of large definitive trials. These therapies appear safe and effective when performed by an experienced clinician. Positive results have been reported in case series and non-randomised and randomised studies with LE from a variety of sport and work-related causes. Future studies using validated clinical measures, and radiological, biomechanical and tissue injury/healing-responsive biomarkers, as secondary outcome measures are needed to determine whether these injection techniques can play a definitive role in a cure for LE and other tendinopathies.

Acknowledgements: Leslie Christensen, MA-LIS, AHIP, Medical Librarian, St. Mary's Hospital Medical Center, for assistance with design and implementation of the search strategy for this study.

Competing interests: DC Massachusetts is a consultant and lecturer for Harvest Technologies of Plymouth, MA, USA, a manufacturer of centrifuge and ancillary equipment for platelet-rich plasma injection therapy. Harvest itself had no direct or indirect role in the production of this manuscript. No other co-author reports any conflict of interest.

REFERENCES

1. **Verhar J.** Tennis elbow: anatomical, epidemiological and therapeutic aspects. *Int Orthop* 1994;**18**:263–7.
2. **Hamilton P.** The prevalence of humeral epicondylitis: a survey in general practice. *J R Coll Gen Pract* 1986;**36**:464–5.
3. **Kivi P.** The etiology and conservative treatment of lateral epicondylitis. *Scand J Rehabil Med* 1983;**15**:37–41.
4. **Ono Y,** Nakamura R, Shimaoka M, *et al*. Epicondylitis among cooks in nursery schools. *Occup Environ Med* 1998;**55**:172–9.
5. **Ritz BR.** Humeral epicondylitis among gas and waterworks employees. *Scand J Work Environ Health* 1995;**21**:478–86.
6. **Hudak PL,** Cole D, Haines T. Understanding prognosis to improve rehabilitation: Example of lateral elbow pain. *Arch Phys Med Rehabil* 1996;**77**:586–93.
7. **Murtaugh JE.** Tennis elbow. *Aust Fam Phys* 1988;**17**:90–5.
8. **Maffulli N,** Khan KM, Kuddu G. Overuse tendon conditions: Time to change a confusing terminology. *Arthroscopy* 1998;**14**:840–3.
9. **Khan KM,** Cook JL, Kannus P, *et al*. Time to abandon the 'tendinitis' myth. *BMJ* 2002;**324**:626–7.
10. **Potter HG,** Hannafin JA, Morwessel RM. Lateral epicondylitis: Correlation of MR imaging, surgical and histopathological findings. *Radiology* 1995;**196**:43–6.
11. **Stasinapoulos D,** Johnson MI. 'Lateral elbow tendinopathy' is the most appropriate diagnostic term for the condition commonly referred to as lateral epicondylitis. *Medical Hypotheses* 2006;**67**:1399–1401.
12. **Kraushaar BS,** Nirschl RP. Tendinitis of the elbow (tennis elbow). Clinical features of histological, immunohistological, and electron microscopy studies. *J Bone Joint Surg* 1999;**81-A**:269–78.
13. **Rees JD,** Wilson AM, Wolman RL. Current concepts in the management of tendon disorders. *Rheumatology* 2006;**45**:508–21.
14. **Bisset L,** Paungmali A, Vicenzino B, *et al*. A systematic review and meta-analysis of clinical trials on physical interventions for lateral epicondylalgia. *Br J Sports Med* 2005;**39**:411–22.
15. **Bisset L,** Beller E, Jull G, *et al*. Mobilization with movement and exercise, corticosteroid injection or wait and see. *BMJ* 2006;**333**:939.
16. **Croiser JL,** Foidart-Dessalle M, Tinant F, *et al*. An isokinetic eccentric program for the management of chronic lateral epicondylar tendinopathy. *Br J Sports Med* 2007;**41**:269–75.
17. **Buchbinder R,** Green S, White M, *et al*. Shock wave therapy for lateral elbow pain. *Cochrane Database Syst Rev* 2005;(4):CD003524.
18. **Smidt N,** van der Windt DA, Assendelft WJ, *et al*. Corticosteroid injections, physiotherapy, or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial. *Lancet* 2002;**359**:657–62.
19. **Struijs PA,** Smidt N, Arola H, *et al*. Orthotic devices for the treatment of tennis elbow. *Cochrane Database Syst Rev*. 2002;(1):CD001821.
20. **Alfredson H,** Ohberg L, Forsgren S. Is vasculo-neural ingrowth the cause of pain in chronic Achilles tendinosis? An investigation using ultrasonography and colour Doppler, immunohistochemistry, and diagnostic injections. *Knee Surg Sports Traumatol Arthrosc* 2003;**11**:334–8.
21. **Alfredson H,** Ohberg L. Neovascularisation in chronic painful patellar tendinosis-promising results after sclerosing neovessels outside the tendon challenge the need for surgery. *Knee Surg Sports Traumatol Arthrosc* 2005;**13**:74–80.
22. **Scott A,** Cook JL, Hart DA, *et al*. Tenocyte responses to mechanical loading in vivo. *Arthritis and Rheumatism* 2007;**56**:871–81.
23. **Zeisig E,** Fahlström M, Ohberg L, *et al*. A 2-year sonographic follow-up after intratendinous injection therapy in patients with tennis elbow. *Br J Sports Med* Published Online First: 29 July 2008. doi:10.1136/bjsm.2008.049874.
24. **Hoksrud A,** Ohberg L, Alfredson H, *et al*. Ultrasound-guided sclerosis of neovessels in painful chronic patellar tendinopathy. *Am J Sports Med* 2006;**34**:1738–46.
25. **Zeisig E,** Fahlström M, Ohberg L, Alfredson H. Pain relief after intratendinous injections in patients with Tennis elbow - results of a randomised study. *Br J Sports Med* 2008;**42**:267–71.
26. **Alfredson H,** Ohberg L. Sclerosing injections to areas of neovascularization reduce pain in chronic Achilles tendinopathy: a double-blind randomised trial. *Knee Surg Sports Traumatol Arthrosc* 2005;**13**:338–44.
27. **Schultz L.** A treatment for subluxation of the temporomandibular joint. *JAMA* 1937;**109**:1032–5.
28. **Dagenais S,** Ogunseitan O, Haldeman S, *et al*. Side effects and adverse events related to intraligamentous injection of sclerosing solutions (prolotherapy) for back and neck pain: a survey of practitioners. *Arch Phys Med Rehabil* 2006;**87**:909–13.
29. **Rabago D,** Best T, Beamsly M, *et al*. A systematic review of prolotherapy for chronic musculoskeletal pain. *Clin J Sports Med* 2005;**15**:376–80.
30. **Topol GA,** Reeves KD, Hassanein KM. Efficacy of dextrose prolotherapy in elite male kicking-sport athletes with groin pain. *Arch Phys Rehabil* 2005;**86**:697–702.
31. **Scarpone M,** Rabago D, Zgierska A, *et al*. The efficacy of prolotherapy for lateral epicondylosis: a pilot study. *Clin J Sports Med* 2008;**18**:248–54.
32. **Suresh SPS,** Ali KE, Jones H, *et al*. Medial epicondylitis: is ultrasound-guided autologous blood injection an effective treatment? *Br J Sports Med* 2006;**40**:935–9.
33. **Connell DA,** Ali KE, Ahmad M, *et al*. Ultrasound-guided autologous blood injection for tennis elbow. *Skeletal Radiol* 2006;**35**:371–7.
34. **Lee TG,** Ahmad TS. Intralesional autologous blood injection compared to corticosteroid injection for treatment of chronic plantar fasciitis. A prospective, randomized, controlled trial. *Foot Ankle Int* 2007;**28**:984–90.
35. **Everts PAM,** Knape JTA, Weibrich GW, *et al*. Platelet-rich plasma and platelet gel: A review. *JECT* 2006;**38**:174–87.
36. **Mishra A,** Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. *Am J Sports Med* 2006;**34**:1774–8.
37. **Gamradt SC,** Rodeo SA, Warren RF. Platelet-rich plasma in rotator cuff repair. *Techniques in Orthopedics* 2007;**22**:26–33.
38. **Randelli PS,** Arrigoni P, Cabitza P, *et al*. Autologous platelet rich plasma for arthroscopic rotator cuff repair. A pilot study. *Disabil Rehabil* 2008;**19**:1–6.
39. **Barrett B.** Datasheet for Assessing Randomized Trials (DART). http://www.fammed.wisc.edu/wurss/1999.
40. **Verhagen AP,** DeVet HCW, DeBie RA, *et al*. The Delphi List: A criteria list for quality assessment of randomized trials conducting reviews developed by Delphi consensus. *JCE* 1998;**51**:1235–41.
41. **Pallant J.** *SPSS Survival Manual: A Step by Step Guide to Data Analysis Using SPSS*. Allen & Unwin, 2007.
42. **Ebell MH,** Siwek J, Weiss BD, *et al*. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. *Am Fam Physician* 2004;**69**:548–56.
43. **Zeisig E,** Ohberg L, Alfredson H. Sclerosing polidocanol injections in chronic painful elbow-promising results in a pilot study. *Knee Surg Sports Traumatol Arthrosc* 2006;**14**:1218–24.
44. **Glick RM.** Prolotherapy for the treatment of lateral epicondylitis: A double-blind pilot study. *North American Research Conference on Complementary and Integrative Medicine*; 24–27 May 2006; Edmonton, Canada.
45. **Lyftogt J.** Subcutaneous prolotherapy treatment of refractory knee, shoulder and lateral elbow pain. *Australasian Musculoskeletal Med* 2007;**12**:110–12.
46. **Gani NU,** Butt MF, Dhar SA, *et al*. Autologous Blood Injection In The Treatment Of Refractory Tennis Elbow. *The Internet Journal of Orthopedic Surgery* 2007;**5**. http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijos/vol5n1/tennis.xml
47. **Edwards SG,** Calandruccio JH. Autologous blood injections for refractory lateral epicondylitis. *J Hand Surgery Am* 2003;**28**:272–8.
48. **Yelland MJ,** Del Mar C, Pirozo S, *et al*. Prolotherapy injections for chronic low back pain: A systematic review. *Spine* 2004;**29**:2126–33.
49. **Farrar JT,** Young JP, LaMoreaux L, *et al*. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical rating scale. *Pain* 2001;**94**:149–58.
50. **Alfredson H,** Cook JL. A treatment algorithm for managing Achilles tendinopathy: new treatment options. *Br J Sports Med* 2007;**41**:211–16.
51. **Zeisig E,** Ohberg L, Alfredson H. Extensor origin vascularity related to pain in patients with tennis elbow. *Knee Surg Sports Traumatol Arthrosc* 2006;**14**:659–63.

52. **Ljung BO,** Alfredson H, Forsgren S. Neurokinin 1-receptors and sensory neuropeptides in tendon insertions at the medial and lateral epicondyles of the humerus. Studies on tennis elbow and medial epicondylalgia. *J Orthop Res* 2004;**22**:321–7.
53. **Fullerton B.** High-resolution ultrasound and magnetic resonance imaging to document tissue repair after prolotherapy: a report of 3 cases. *Arch Phys Med Rehabil* 2008;**89**:377–85.
54. **Maxwell NJ,** Ryan MB, Taunton JE, *et al*. Sonographically guided intratendinous injection of hyperosmolar dextrose to treat chronic tendinosis of the Achilles tendon: a pilot study. *AJR Am J Roentgenol* 2007;**189**:W215–W220.
55. **Banks A.** A rationale for prolotherapy. *Journal of Orthopaedic Medicine* 1991;**13**:54–9.
56. **Jensen K,** Rabago D, Best TM, *et al*. Early inflammatory response of knee ligaments to prolotherapy in a rat model. *J Orthop Res* 2008;**26**:816–23.
57. **Jensen KT,** Rabago D, Best TM, *et al*. Longer term response of knee ligaments to prolotherapy in a rat injury model. *Am J Sports Med* 2008;**36**:1347–57.
58. **Liu YK,** Tipton CM, Matthes RD, *et al*. An in-situ study of the influence of a sclerosing solution in rabbit medial collateral ligaments and its junction strength. *Connect Tissue Res* 1983;**11**:95–102.
59. **Aneja A,** Spero G, Weinhold P, *et al*. Suture plication, thermal shrinkage and sclerosing agents. *Am J Sports Med* 2005;**33**:1729–34.
60. **Okuda Y,** Adrogue H, Nakajima T, *et al*. Increased production of PDGF by angiotensin and high glucose in human vascular endothelium. *Life Sci* 1996;**59**:1455–61.
61. **Oh JH,** Ha H, Yu MR, *et al*. Sequential effects of high glucose on mesangial cell transforming growth factor-B1 and fibronectin synthesis. *Kidney Int* 1998;**54**:1872–8.
62. **DiPaolo S,** Gesualdo L, Ranieri E, *et al*. High glucose concentration induces the overexpression of transforming growth factor-B1 through the activation of a platelet-derived growth factor loop in human mesangial cells. *Am J Pathol* 1996;**149**:2095–106.
63. **Zochodne DW.** Local events within the injured and regenerating peripheral nerve trunk: The role of the microenvironment and microcirculation. *Biomedical Review* 1997;**8**:37–54.
64. **Schnabel LV,** Mohammed HO, Miller BJ. Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum supeficialis tendons. *J Orthop Res* 2007;**25**:230–40.
65. **Anitua E,** Andia I, Sanchez M. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. *J Orthop Res* 2005;**23**:281–6.
66. **Anitua E,** Sanchez M, Nurden AT. Autologous fibrin matrices: a potential source of biological mediators that modulate tendon activities. *J Biomed Mater Res* 2006;**77**:285–93.
67. **Murray MM,** Spindler KP, Abreu E. Collagen-platelet rich plasma hydrogel enhances primary repair of the porcine anterior cruciate ligament. *J Orthop Res* 2007;**25**:81–91.
68. **Murray MM,** Spindler KP, Devin C. Use of a collagen-platelet rich plasma scaffold to stimulate healing of a central defect in the canine. *J Orthop Res* 2006;**24**:820–30.